Conference Correspondent

Highly sensitive cardiac troponin may provide prognostic information on long-term cardiovascular (CV) event risk assessment in patients with rheumatoid arthritis (RA) without prior diagnosis of CV disease.
In this post-hoc analysis of the AMPLE trial, subcutaneous (SC) abatacept treatment was associated with lower cost per responder compared with SC adalimumab in patients with seropositive, erosive early rheumatoid arthritis (RA).
In this long-term efficacy and safety analysis of the global phase 3 SIRROUND-D trial, improvements in signs and symptoms of rheumatoid arthritis (RA) and health-related physical and emotional well-being were maintained with sirukumab treatment in patients with active RA despite disease-modifying antirheumatic drugs (DMARDs).
Results of the randomized, placebo-controlled, phase 3 SELECT-NEXT study showed that upadacitinib, a selective JAK-1 inhibitor, at 15 mg and 30 mg once daily, was efficacious in patients with rheumatoid arthritis (RA) who had inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs), with a safety and tolerability profile that was consistent with that previously reported.
An updated integrated analysis of patients (n = 3492) with moderately to severely active rheumatoid arthritis (RA), including patients exposed to any dose of baricitinib for up to 5.5 years, showed that the safety profile of baricitinib was maintained as similar to that previously reported.
A cardiac MRI follow-up study showed that patients with active rheumatoid arthritis (RA) show myocardial abnormalities at baseline, which significantly improved in patients with early RA following active treatment for 1 year.
A real-world analysis of electronic health record (EHR) databases across Integrated Delivery Networks showed lower EHR reporting rates of clinical and disease severity measures, thus compromising the ability of rheumatologists to adopt a guideline-recommended treat-to-target approach in clinical practice.
Results from a systematic review and network meta-analysis of randomized controlled trials showed that tofacitinib 10 mg and baricitinib 8 mg combined with methotrexate were both effective in patients with rheumatoid arthritis (RA), with similar safety outcomes.
A large multidatabase, population-representative cohort study showed a similar risk for primary composite cardiovascular events between patients with rheumatoid arthritis (RA) who newly started tocilizumab and abatacept starters.
This 4-year follow-up of the phase 3 RESONATE study provides updated data on the efficacy and safety of ibrutinib, comparing the long-term efficacy and safety of ibrutinib versus ofatumumab in patients with chronic lymphocytic leukemia (CLL).
Page 2 of 8
Results 11 - 20 of 80
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME